Year All20242023202220212020201920182017201620152014 Jun 24, 2020 Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock Jun 23, 2020 Soleno Therapeutics Announces Proposed Public Offering of Common Stock Jun 08, 2020 Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome May 12, 2020 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results Apr 23, 2020 Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity Mar 11, 2020 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference Mar 04, 2020 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results Jan 06, 2020 Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome Nov 13, 2019 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results Oct 25, 2019 Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock
Jun 08, 2020 Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
May 12, 2020 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
Apr 23, 2020 Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity
Mar 04, 2020 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
Jan 06, 2020 Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
Nov 13, 2019 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results